Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

Inclusion Criteria:

The Core Protocol inclusion criteria are:

• Provision of signed and dated, written Informed Consent Form (ICF).

• Patient is currently deriving clinical benefit, as judged by the investigator, fromcontinued treatment in an AstraZeneca parent study using an AstraZeneca compoundthat has met its endpoints, or has otherwise stopped, or the patient has reachedmaximum treatment duration allowed in the parent study's protocol.

• Patient can receive durvalumab as a fixed dose of 1500 mg quarterly 4 weeks at studyentry.

There are no additional inclusion criteria for the ROSY-D sub-study.

Exclusion Criteria:

The Core Protocol exclusion criteria are.

• Ongoing, unresolved, Grade 3 or above toxicity requiring interruption of treatmentat the time of the termination of the parent study.

• Currently receiving treatment with any prohibited medication(s).

• Concurrently enrolled in any other type of medical research judged not to bescientifically or medically compatible with this study.

• Permanent discontinuation from the parent study due to toxicity or diseaseprogression (increase in the severity of the disease under study and/or increases inthe symptoms of a patient's condition attributable to the disease, as assessed anddocumented by the Investigator. Physician-defined progression can be radiological [example: Response Evaluation Criteria in Solid Tumours] progression or clinicalprogression).

• Local access to commercially-available drug at no cost to the patient as permittedby local/country regulation.

The additional exclusion criteria for the ROSY-D sub-study are:

• Active infection including Coronavirus disease 2019 (Polymerase chain reactionconfirmed and/or clinically suspected), tuberculosis, hepatitis B (known positiveHepatitis B virus (HBV) surface antigen result), hepatitis C, or Humanimmunodeficiency virus (HIV) (positive HIV 1/2 antibodies).

• Male or female patients of reproductive potential who are not willing to employeffective birth control from study inclusion up to 90 days after the last dose ofdurvalumab monotherapy.

• Ongoing, unresolved, Grade 2 toxicity with an inability to reduce corticosteroid toa dose of ≤ 10 mg of prednisone per day (or equivalent) within 12 weeks after lastdose of study treatment/study regimen, per Toxicity Dose Modification and TMGs forImmune- mediated, Infusion-related, and Non-Immune-mediated Reactions Guidelines ofthe parent study.